StockNews.com assumed coverage on shares of Pulmatrix (NASDAQ:PULM – Get Rating) in a report issued on Wednesday. The brokerage set a “hold” rating on the biotechnology company’s stock.
Separately, HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Pulmatrix in a research report on Tuesday, February 7th.
Pulmatrix Stock Down 6.9 %
Shares of NASDAQ PULM opened at $2.67 on Wednesday. The business’s 50 day moving average price is $2.88 and its 200 day moving average price is $3.43. The firm has a market cap of $9.75 million, a P/E ratio of -0.52 and a beta of 0.76. Pulmatrix has a 52 week low of $2.63 and a 52 week high of $7.50.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in PULM. Citadel Advisors LLC acquired a new stake in Pulmatrix in the 2nd quarter worth about $141,000. Mariner LLC bought a new stake in shares of Pulmatrix in the 4th quarter valued at approximately $97,000. Susquehanna International Group LLP acquired a new position in Pulmatrix during the 1st quarter valued at approximately $73,000. Finally, Renaissance Technologies LLC boosted its position in Pulmatrix by 7.3% during the 2nd quarter. Renaissance Technologies LLC now owns 121,920 shares of the biotechnology company’s stock valued at $560,000 after purchasing an additional 8,300 shares during the period. Hedge funds and other institutional investors own 15.69% of the company’s stock.
Pulmatrix, Inc is a clinical stage biotechnology company, which engages in the development and discovery of novel inhaled therapeutics products. The company was founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov, and Robert S. Langer, Jr. on June 15, 2015 and is headquartered in Lexington, MA.
- Get a free copy of the StockNews.com research report on Pulmatrix (PULM)
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
- Best Buy’s Comeback Is Still At Play, Earnings Call For Patience
- e.l.f. Beauty Has Giant Quarter, Shares Hit New High
- If You Can Only Pick One Stock For The Rest Of 2023, Pick Nvidia
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.